LIC

New Quality Control Systems for Every Laboratory Application

Quality Control (QC) materials and procedures are key to meeting the needs of doctors and patients by verifying accuracy and precision of analytical methods. Vendors of these systems can be a valuable resource, designing customized QC materials and protocols to help lab managers ensure that analytical error st...

Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer - LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- ResponseGenetics, Inc. today announced that positive Phase III clinicaldata published in the July 1 issue of the Journal of ClinicalOncology suggests that low expression of the biomarkerExcision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsieswith advanced non-...

NIEHS Researchers Identify Enzyme Critical in DNA Replication

BETHESDA, Md., July 5, 2007--In this weeks issue of Science,researchers from the National Institute of Environmental HealthSciences (NIEHS) and Umeö University in Sweden report animportant discovery about a critical new role that an enzyme calledDNA polymerase epsilon plays in replicating DNA in higher organismssuch as yeast and perhaps even humans. The study places us one ste...

DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC

MIAMI--(MARKET WIRE) -- July 02, 2007 -- DOR BioPharma, Inc.(OTCBB: DORB) ("DOR" or the "Company") announced today that thefirst results from testing of a multivalent form of its botulinumtoxin vaccine, BT-VACC™, have been published in the journalInfection and Immunity (Ravichandran et al., 2007, Infection andImmunity, v. 75, p. 3043 ). These results are the first thatdescribe the...

Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - CyclacelPharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced todaythe results from two Phase II non-randomized studies of seliciclibfixed dose combinations. In one study seliciclib was given incombination with gemcitabine and cisplatin and in another withdocetaxel in patients with advanced non-small cell lung cancer(NSCLC).<p...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpreliminary results from two open-label, multi-center Phase 2clinical trials supporting the potential use of Xcytrin(R)(motexafin gadolinium) Injection, the company's lead productcandidate, in combination with Alimta(R) (pemetrexed) and incombination with Taxotere(R) (docetaxel...

Publication Confirms that EpCAM, the Target for Two of Micromet's Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers

BETHESDA, Md., June 26, 2007 /PRNewswire-FirstCall/ -- Micromet,Inc. , a biopharmaceutical company focusing on the development ofnovel, proprietary antibody-based products for cancer, inflammatoryand autoimmune diseases, announced that a study published recentlyin the Proceedings of the National Academy of Sciences (1) supportsthe findings of several other studies that EpCAM (CD326), whic...

Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 26, 2007 - SirtrisPharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical companyfocused on discovering and developing small molecule drugs to treatdiseases of aging, announced today that activation of SIRT1, amember of the sirtuin family of enzymes, was shown to protectagainst neurodegenerative diseases such as Alzheimer's Disease andAmyotrophic Lat...

Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone

Interim results in a randomized phase II/III clinical trialanticipated later this year SEATTLE, June 26, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced the publication of preclinicalstudies, which demonstrate that treatment with pixantrone (BBR2778) resulted in minimal or no significant cardiotoxicity, whiledoxorubicin and mitoxantrone induced significant cardiac da...

Materia Licenses Metathesis Catalyst Platform to Eisai

PASADENA, Calif.--(BUSINESS WIRE)--Jun 20, 2007 - Materia, Inc., acatalyst technology company, announced today the licensing of itsmetathesis platform to Eisai Co., Ltd., a leading Japanesepharmaceutical company, for use in drug discovery and development.The non-exclusive license agreement provides rights to discover,develop, and patent pharmaceutical compounds and related processesusing th...

Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinson's Disease

FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Neurologix, Inc.(OTCBB:NRGX) today announced the publication in the June 23 issueof the journal The Lancet of positive results from the first evergene therapy trial for Parkinson's disease and the first report ofdirect gene transfer into a patient's own brain cells for any adultneurodegenerative disease. The open label Phase 1 study, conduct...

Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology

SAN CARLOS, Calif., June 19, 2007 /PRNewswire-FirstCall/ --Nuvelo, Inc. today announced the publication of the Phase 2proof-of-concept data from the Anthem (Anticoagulation with rNAPc2To Help Eliminate MACE)/TIMI 32 clinical trial (N=255) in the June26th issue of the Journal of of Cardiology (JACC), demonstratingthat higher-dose (greater than or equal to 7.5 mcg/kg) recombinantnematode a...

Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan

SAN DIEGO, June 18, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that the company's licensee, AnGes MG,Inc. reported positive results following interim analysis of datafrom the first 41 subjects to complete a Phase 3 trial of anangiogenesis product candidate using Vical's DNA deliverytechnology. Based on the findings that the primary efficacyendpoint in the trial had...

Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits

NEW YORK, June 15, 2007 /PRNewswire/ -- Telomerase ActivationSciences, Inc. (T.A. Sciences) recently announced the results ofthe Pivotal 2005 Anti-Aging Trial of TA-65, the first human trialever to show demonstrated, measurable and positive anti-agingbenefits from a Telomerase Activator. Statistically significantresults were found in those taking TA-65 across several keyconditions of agi...

Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - CriticalTherapeutics, Inc. (Nasdaq: CRTX) today announced the publicationof data from a pivotal Phase III clinical trial of ZYFLO CR(TM)(zileuton) extended-release tablets in the June 2007 issue of theJournal of Asthma. ZYFLO CR was approved by the U.S. Food and DrugAdministration (FDA) on May 30, 2007. Critical Therapeutics,together with it...

Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas

SAN CARLOS, Calif., June 05, 2007 /PRNewswire-FirstCall/ --Nuvelo, Inc. today announced the publication of data from apreclinical study of novel monoclonal antibodies against thecell-surface protein NTB-A. The data demonstrate that NTB-A is apotential new target for immunotherapy of B-cell malignanciesincluding leukemia and lymphomas. The study, entitled "The lymphoidcell surface recepto...

Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO

MONTRÉAL, June 1, 2007 – Thallion Pharmaceuticals Inc.(TSX: TLN) announced today that preliminary data from its PhaseI/II clinical trial investigating ECO-4601 in advanced cancerpatients was published in abstract form as part of the AmericanSociety of Clinical Oncology (ASCO) Annual Meeting in Chicago,Illinois. In the Phase I dose escalation portion of the study, 14patients (te...

Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer

- Data Support Rationale for Comprehensive Ongoing Phase 2 Programas Combination Agent with Standard Chemotherapies and Pivotal LungCancer Trial Scheduled to Begin Early Next Year - CHICAGO and SUNNYVALE, Calif. June 01, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpromising preliminary results from an open-label Phase 2 clinicaltrial of Xcytrin(R) (motexafin gadoliniu...

Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard Researcher

STANFORD, Calif.--(BUSINESS WIRE)--May 30, 2007 - People with aclass of rare genetic disorders that often lead to brain damage,coma and death can be successfully treated with drugs, says aresearcher at the Stanford University School of Medicine and LucilePackard Children's Hospital. The researchers found in their unprecedented 25-year study thatprompt diagnosis coupled with a rapid start...

Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates

SEATTLE, May 31, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that a measles DNA vaccine formulatedwith the company's Vaxfectin(TM) adjuvant elicited protectivelevels of neutralizing antibodies in juvenile (1 - 2 year old)nonhuman primates confirmed by complete protection followingchallenge more than one year after vaccination, and sterilizingimmunity as evidenced by...

Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting

SUNNYVALE, Calif., May 23, 2007 /PRNewswire-FirstCall/ --Pharmacyclics, Inc. announced today multiple presentations and apublished abstract regarding Xcytrin(R) (motexafin gadolinium)Injection, including an oral presentation of Phase 3 SMART (Studyof Neurologic Progression with Motexafin Gadolinium And RadiationTherapy) trial data. The presentations and publications are part ofthe procee...

Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database

PRINCETON, N.J.--(BUSINESS WIRE)--May 23, 2007 - CytogenCorporation (NASDAQ: CYTO) today reported the publication of areview validating the utility of its ProChart(TM) database to helpdefine the function of the WW domain-containing oxidoreductase(WWOX), an important tumor suppressor gene with known involvementin breast, prostate, lung, pancreatic, esophageal, and gastriccancers. The peer-re...

Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex

MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--May21, 2007 - ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) notesthe publication of new clinical data relevant to the developmentstrategy for Ceflatonin(R) (homoharringtonine). The paper "Targetedtherapy and the T315I mutation in Philadelphia-positive leukemias"by researchers Simona Soverini and colleagues at the University...

Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril

Comparison of BENICAR HCT 40/12.5 and 40/25 mg/day and Amlodipine +Benazepril 5/20 and 10/20 mg/day Presented at American Society ofHypertension Twenty-Second Annual Scientific Meeting PARSIPPANY, N.J., May 21, 2007 /PRNewswire/ -- New datapresented today at the American Society of Hypertension'sTwenty-Second Annual Scientific Meeting (ASH 2007) in Chicagodemonstrated that the fixed-dose...

Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex

MELBOURNE, Australia, and MENLO PARK, CaliforniaU.S.A. (May 21, 2007): ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ:CXSP) notes the publication of new clinical data relevant to thedevelopment strategy for Ceflatonin® (homoharringtonine). Thepaper "Targeted therapy and the T315I mutation inPhiladelphia-positive leukemias" by researchers Simona Soverini andcolleagues at...

Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin in Complicated Urinary Tract Infections and Acute Pyelonephritis

ANAHEIM, Calif., May 19, 2007 /PRNewswire/ -- Data presentedtoday at a major medical meeting found that Levaquin (levofloxacin)750 mg tablets administered once-daily for five days is aseffective as standard therapy of ciprofloxacin (400/500 mg) for 10days for the treatment of complicated urinary tract infections(cUTI) and acute pyelonephritis (AP). Ortho-McNeil, Inc., the company t...

Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma

MONTREAL--(BUSINESS WIRE)--May 15, 2007 - Gemin X BiotechnologiesInc. announced today that a report published in the journal Blooddemonstrated that its lead compound, obatoclax (GX15-070), inducedcell death in vitro in Mantle Cell Lymphoma (MCL) cell lines andprimary cells from 11 MCL patients. Obatoclax (GX15-070) is a smallmolecule specifically designed to inhibit all relevant members oft...

GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines

Investigational vaccine could offer protectionfor infants against type b andmeningococcal disease — GlaxoSmithKline (GSK) announced results from aPhase II vaccine clinical study presented this week at thePediatri...

Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor AP 12009 to be Presented

REGENSBURG, Germany, May 10th, 2007 - AntisensePharma today announced, that the abstract entitled“Preliminary Results of a Phase I/II-Study in PancreaticCarcinoma, Malignant Melanoma, and Colorectal Carcinoma with theTGF-beta2 Inhibitor AP 12009” has been selected for posterpresentation at the 43rd Annual Meeting of the American Society ofClinical Oncology (ASCO)...

Independent publication supports the profile of CeNeS phase II compound, CNS 5161

CAMBRIDGE, England, 4th May 2007 - CeNeS Pharmaceuticals plc(LSE: CEN), the Cambridge based biopharmaceutical company, notesthe publication of an independent study in the respected scientificjournal 'Synapse'* on its Phase II NMDA antagonist, CNS 5161. CeNeSis developing CNS 5161 as a potential treatment for neuropathicpain. The independent study builds on the work that CeNeS hasalready...

Ties Between Physicians and Drug Companies Still Too Strong: the Prescription Project Offers Solutions to Prevent Conflicts of Interest

BOSTON--(BUSINESS WIRE)--Apr 26, 2007 - A new study published todayin the New England Journal of Medicine ("A National Survey ofPhysician-Industry Relationships") on the extent of doctor andpharmaceutical company relationships, highlights the need forprofession-wide and public policy reforms promoted by ThePrescription Project. The article concludes that the existing,voluntary PhRMA (Pharma...

CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal

LOS ANGELES--(BUSINESS WIRE)--Apr 23, 2007 - CytRx Corporation(NASDAQ:CYTR) today announced that the RNA interference (RNAi)delivery technology exclusively licensed to its majority-ownedsubsidiary, RXi Pharmaceuticals Corporation (RXi), has beenpublished in the April 2007 issue of peer-reviewed scientificjournal ACS Chemical Biology. The technology was developed by RXiCo-founder, Scientific...

Ceragenix Announces New Publication of Scientific Research on Ceragenin Technology

DENVER--(BUSINESS WIRE)--Apr 23, 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmaceutical company focused oninfectious disease and dermatology, today announced the publicationof a research paper on two of the Company's antimicrobialcompounds: CSA-8 and CSA-13. The paper appeared in the April issueof the Journal of Antimicrobial Agents and Chemotherapy, apeer-reviewed official...

Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR

Myriad Genetics Presents Studies Characterizing Vascular DisruptionCapabilities of Azixa(TM) TARRYTOWN, N.Y., April 20, 2007 /PRNewswire-FirstCall/ --EpiCept Corporation reported today that studies characterizing adual mode of action for Azixa(TM), a compound licensed by theCompany to Myriad Genetics, Inc. for the treatment of primary andsecondary brain tumors, were presented at the annua...

Critical Therapeutics Announces the Publication of New Preclincial HMGB1 Data in Nature Immunology

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - CriticalTherapeutics, Inc. (Nasdaq: CRTX) today announced that newpreclinical research demonstrating a role in chronic inflammatoryautoimmune disease for High Mobility Group Box-1 protein (HMGB1), apro-inflammatory mediator and nuclear DNA-binding protein, will bepublished in the May 2007 issue of Nature Immunology. Thepublication demonstrat...

Antares Pharma Announces Positive Results from Application Site Study for Anturol

EWING, N.J.--(BUSINESS WIRE)--Apr 19, 2007 - Antares Pharma, Inc.(AMEX: AIS) announced positive results from a recently completedsite application study demonstrating that ANTUROL(R), it'soxybutynin ATD(TM) transdermal gel, was absorbed on a bioequivalentbasis after a single-dose was applied to three different skin sitelocations. The study was an open-label, comparative three-way crossover...

Aeolus Pharmaceuticals' AEOL 10150 Highlighted in Nature Genetics Publication

LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Apr 18, 2007 - AeolusPharmaceuticals, Inc. (OTCBB:AOLS) announced today that a newreport published in the medical journal, Nature Genetics (Tong etal. Nature Genetics 39:476-485, 2007), showed that AeolusPharmaceuticals' lead compound AEOL 10150 (MnTDEIP) can improvesurvival in fruit flies genetically lacking the neurofibromatosis-1(NF1) gene. These m...

Idera Pharmaceuticals Announces Presentations of Preclinical Data on New Potential Oncology Applications of its TLR9 Agonists at AACR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - IderaPharmaceuticals, Inc. (AMEX: IDP) today announced two presentationsof data for two new potential applications in oncology of its novelagonists of Toll-like receptor 9 (TLR9) at the Annual Meeting ofthe American Association for Cancer Research (AACR) being held inLos Angeles, CA, April 14-18, 2007. The first presentation covereda preclin...

Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Bruton's Tyrosine Kinase Inhibitors

SUNNYVALE, Calif. and LOS ANGELES, April 18, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced datafrom two preclinical studies, one identifying a functionalbiomarker for its novel histone deacetylase (HDAC) inhibitor andanother demonstrating preclinical anti-tumor activity with itsBruton's tyrosine kinase (BTK) inhibitor compounds. The data werepresented at the American...

Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2 Study Data in Neurology

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Apr 10, 2007 - ValeantPharmaceuticals International (NYSE:VRX) announced today thepublication of Phase 2 data for retigabine, a first-in-classneuronal potassium channel opener, in Neurology, a leadingindependent, scientific journal. The authors concluded thatretigabine was efficacious with a demonstrated reduction in monthlyseizure rates in this study....